Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

RNA Avidity Biosciences, Inc. Common Stock
$13.62 3.18% +0.42
Notify me if price changes either direction
Interactive Brokers Logotype

Buy RNA stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 233.0M
Enterprise value -36422512
Trailing PE -4.6996379832574
Forward PE -1.637717
PEG Ratio -0.095461396534917
Enterprise to EBITDA 0.531
Enterprise to revenue -1.016
Price to book MRQ 0.9644893
Price to sales TTM 6.300597

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 35.8M
EBITDA -68528000
Diluted EPS TTM -5.44
Total Cash (MRQ) 263.9M
Current ratio (MRQ) 8.73
Operating Cash Flow (TTM) -53188000

RNA trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent RNA News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.